BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17043157)

  • 1. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
    Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
    Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
    Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
    Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
    Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone improves angiotensin-induced vascular changes and oxidative stress.
    Virdis A; Neves MF; Amiri F; Viel E; Touyz RM; Schiffrin EL
    Hypertension; 2002 Oct; 40(4):504-10. PubMed ID: 12364354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
    Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
    J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
    Huang BS; White RA; Ahmad M; Leenen FH
    Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
    Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
    Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
    Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
    Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man.
    Cuneo RC; Espiner EA; Nicholls MG; Yandle TG; Livesey JH
    J Clin Endocrinol Metab; 1987 Oct; 65(4):765-72. PubMed ID: 2821056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
    Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
    Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor.
    Dinh QN; Young MJ; Evans MA; Drummond GR; Sobey CG; Chrissobolis S
    Brain Res; 2016 Apr; 1637():146-153. PubMed ID: 26923165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.
    Arnold AC; Okamoto LE; Gamboa A; Black BK; Raj SR; Elijovich F; Robertson D; Shibao CA; Biaggioni I
    Hypertension; 2016 Feb; 67(2):424-9. PubMed ID: 26644241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study.
    Ojeda-Cervantes M; Barrera-Chimal J; Alberú J; Pérez-Villalva R; Morales-Buenrostro LE; Bobadilla NA
    Am J Nephrol; 2013; 37(5):481-90. PubMed ID: 23635604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Gantman A; Coleman R; Keidar S
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):228-35. PubMed ID: 23223089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.
    Cassis LA; Helton MJ; Howatt DA; King VL; Daugherty A
    Br J Pharmacol; 2005 Feb; 144(3):443-8. PubMed ID: 15655500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.